PT1257292E - Utilização de inibidores de il-18 - Google Patents
Utilização de inibidores de il-18 Download PDFInfo
- Publication number
- PT1257292E PT1257292E PT01911662T PT01911662T PT1257292E PT 1257292 E PT1257292 E PT 1257292E PT 01911662 T PT01911662 T PT 01911662T PT 01911662 T PT01911662 T PT 01911662T PT 1257292 E PT1257292 E PT 1257292E
- Authority
- PT
- Portugal
- Prior art keywords
- inhibitors
- medicament
- prevention
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00103597 | 2000-02-21 | ||
| EP00103590 | 2000-02-21 | ||
| EP00121651 | 2000-10-04 | ||
| EP00125633 | 2000-11-23 | ||
| PCT/EP2001/001867 WO2001062285A1 (en) | 2000-02-21 | 2001-02-20 | Use of il-18 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1257292E true PT1257292E (pt) | 2011-07-05 |
Family
ID=27439934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01911662T PT1257292E (pt) | 2000-02-21 | 2001-02-20 | Utilização de inibidores de il-18 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20030157094A1 (pt) |
| EP (1) | EP1257292B1 (pt) |
| JP (1) | JP4744763B2 (pt) |
| KR (3) | KR20020086540A (pt) |
| CN (1) | CN1322897C (pt) |
| AT (1) | ATE506959T1 (pt) |
| AU (2) | AU2001240636B8 (pt) |
| BG (1) | BG66134B1 (pt) |
| BR (1) | BR0108514A (pt) |
| CA (2) | CA2399298C (pt) |
| CY (1) | CY1111687T1 (pt) |
| CZ (1) | CZ304485B6 (pt) |
| DE (1) | DE60144514D1 (pt) |
| DK (1) | DK1257292T3 (pt) |
| EA (1) | EA005583B1 (pt) |
| EE (1) | EE05423B1 (pt) |
| HK (1) | HK1051965A1 (pt) |
| HR (1) | HRP20020652A2 (pt) |
| HU (1) | HU227752B1 (pt) |
| IL (2) | IL151388A0 (pt) |
| ME (1) | ME00546B (pt) |
| MX (1) | MXPA02008079A (pt) |
| NO (1) | NO331971B1 (pt) |
| NZ (3) | NZ520122A (pt) |
| PL (1) | PL206549B1 (pt) |
| PT (1) | PT1257292E (pt) |
| RS (1) | RS51737B (pt) |
| SI (1) | SI1257292T1 (pt) |
| SK (1) | SK288032B6 (pt) |
| TR (2) | TR200502508T2 (pt) |
| WO (1) | WO2001062285A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101111103B1 (ko) * | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
| TR200502508T2 (tr) * | 2000-02-21 | 2007-04-24 | Applied Research Systems Ar� Holding N.V. | IL-18 İnhibitörlerinin kullanımı. |
| EP1331943A4 (en) | 2000-10-11 | 2005-01-26 | Viron Therapeutics Inc | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION |
| US7718368B2 (en) | 2000-12-04 | 2010-05-18 | Viron Therapeutics Inc. | Immunomodulatory protein and useful embodiments thereof |
| US20030008822A1 (en) * | 2001-05-16 | 2003-01-09 | Charles Dinarello | Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| WO2003045400A1 (en) * | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| WO2004064713A2 (en) * | 2003-01-20 | 2004-08-05 | Vib Vzw | The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors |
| AU2004235595C1 (en) * | 2003-04-30 | 2009-09-24 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| AU2004290413A1 (en) * | 2003-11-10 | 2005-05-26 | Vertex Pharmaceuticals Incorporated | Methods for monitoring IL-18 |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| US20090004683A1 (en) | 2004-06-30 | 2009-01-01 | Atsuo Sekiyama | Indicator Agent for Noninflammatory Stress Response and Use Thereof |
| WO2006009114A1 (ja) * | 2004-07-16 | 2006-01-26 | Atsuo Sekiyama | Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物 |
| US7691611B2 (en) | 2005-06-03 | 2010-04-06 | Ares Trading S.A. | Production of recombinant IL-18 binding protein |
| JP5091127B2 (ja) | 2005-06-10 | 2012-12-05 | アレス トレーディング ソシエテ アノニム | Ｉｌ−１８結合タンパク質の精製のための方法 |
| EP1746167A1 (en) * | 2005-07-20 | 2007-01-24 | Apoxis SA | Method for the identification of compounds susceptible to inhibit inflammation |
| BRPI0711908B8 (pt) | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
| US8440195B2 (en) * | 2010-11-12 | 2013-05-14 | National University Corporation Chiba University | Inhibition of CD69 for treatment of inflammatory conditions |
| GB201213968D0 (en) * | 2012-08-06 | 2012-09-19 | Isis Innovation | Prevention and treatment of osteoarthritis |
| EP3978526A1 (en) * | 2013-09-05 | 2022-04-06 | AB2 Bio SA | Il-18 binding protein (il-18bp) in inflammatory diseases |
| US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
| CN106109497A (zh) * | 2016-07-25 | 2016-11-16 | 深圳爱生再生医学科技有限公司 | 治疗肝硬化的干细胞制剂 |
| CN106834449B (zh) * | 2017-01-10 | 2019-04-30 | 东南大学 | 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 |
| JP2021527107A (ja) * | 2018-06-14 | 2021-10-11 | ユニベルシテ ドゥ ボルドー | インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療 |
| EP4371573A1 (en) | 2021-07-13 | 2024-05-22 | National University Corporation Tokai National Higher Education and Research System | Medicinal composition for treating inflammatory bowel disease |
| CN117647645B (zh) * | 2024-01-29 | 2024-04-12 | 中国人民解放军总医院第一医学中心 | Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985863A (en) * | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5744451A (en) * | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| WO1998022137A1 (en) * | 1996-11-15 | 1998-05-28 | The Kennedy Institute Of Rheumatology | SUPPRESSION OF TNF α AND IL-12 IN THERAPY |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| US6087116A (en) * | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
| JP4026923B2 (ja) * | 1997-03-12 | 2007-12-26 | 株式会社林原生物化学研究所 | ポリペプチド |
| IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| EP1110969A4 (en) * | 1998-09-01 | 2002-01-09 | Hayashibara Biochem Lab | INTERLEUKIN 18 BINDING PROTEIN |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| KR101111103B1 (ko) * | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
| TR200502508T2 (tr) * | 2000-02-21 | 2007-04-24 | Applied Research Systems Ar� Holding N.V. | IL-18 İnhibitörlerinin kullanımı. |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
-
2001
- 2001-02-20 TR TR2005/02508T patent/TR200502508T2/xx unknown
- 2001-02-20 NZ NZ520122A patent/NZ520122A/en not_active IP Right Cessation
- 2001-02-20 PL PL357554A patent/PL206549B1/pl unknown
- 2001-02-20 DK DK01911662.3T patent/DK1257292T3/da active
- 2001-02-20 SI SI200130994T patent/SI1257292T1/sl unknown
- 2001-02-20 MX MXPA02008079A patent/MXPA02008079A/es active IP Right Grant
- 2001-02-20 SK SK1208-2002A patent/SK288032B6/sk not_active IP Right Cessation
- 2001-02-20 AT AT01911662T patent/ATE506959T1/de active
- 2001-02-20 JP JP2001561349A patent/JP4744763B2/ja not_active Expired - Lifetime
- 2001-02-20 KR KR1020027010645A patent/KR20020086540A/ko not_active Application Discontinuation
- 2001-02-20 CA CA2399298A patent/CA2399298C/en not_active Expired - Lifetime
- 2001-02-20 KR KR1020077010853A patent/KR20070057282A/ko not_active Application Discontinuation
- 2001-02-20 EE EEP200200463A patent/EE05423B1/xx unknown
- 2001-02-20 IL IL15138801A patent/IL151388A0/xx unknown
- 2001-02-20 AU AU2001240636A patent/AU2001240636B8/en not_active Expired
- 2001-02-20 TR TR2002/02030T patent/TR200202030T2/xx unknown
- 2001-02-20 PT PT01911662T patent/PT1257292E/pt unknown
- 2001-02-20 HU HU0300061A patent/HU227752B1/hu unknown
- 2001-02-20 BR BR0108514-0A patent/BR0108514A/pt not_active Application Discontinuation
- 2001-02-20 US US10/204,387 patent/US20030157094A1/en not_active Abandoned
- 2001-02-20 EA EA200200890A patent/EA005583B1/ru not_active IP Right Cessation
- 2001-02-20 CA CA2683009A patent/CA2683009C/en not_active Expired - Lifetime
- 2001-02-20 NZ NZ535299A patent/NZ535299A/en not_active IP Right Cessation
- 2001-02-20 CN CNB018052932A patent/CN1322897C/zh not_active Expired - Lifetime
- 2001-02-20 CZ CZ2002-2843A patent/CZ304485B6/cs not_active IP Right Cessation
- 2001-02-20 NZ NZ546294A patent/NZ546294A/en not_active IP Right Cessation
- 2001-02-20 WO PCT/EP2001/001867 patent/WO2001062285A1/en active IP Right Grant
- 2001-02-20 EP EP01911662A patent/EP1257292B1/en not_active Expired - Lifetime
- 2001-02-20 DE DE60144514T patent/DE60144514D1/de not_active Expired - Lifetime
- 2001-02-20 ME MEP-2008-639A patent/ME00546B/me unknown
- 2001-02-20 KR KR1020077018043A patent/KR20070087256A/ko not_active Application Discontinuation
- 2001-02-20 RS YU60402A patent/RS51737B/sr unknown
- 2001-02-20 AU AU4063601A patent/AU4063601A/xx active Pending
-
2002
- 2002-08-01 HR HRP20020652 patent/HRP20020652A2/hr not_active Application Discontinuation
- 2002-08-20 NO NO20023962A patent/NO331971B1/no not_active IP Right Cessation
- 2002-08-20 BG BG107018A patent/BG66134B1/bg unknown
- 2002-08-21 IL IL151388A patent/IL151388A/en active IP Right Grant
-
2003
- 2003-06-12 HK HK03104196A patent/HK1051965A1/xx unknown
-
2011
- 2011-07-13 CY CY20111100682T patent/CY1111687T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1051965A1 (en) | Use of il-18 inhibitors | |
| HRP20130602T1 (en) | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases | |
| IL158088A0 (en) | Remedies for inflammatory bowel diseases | |
| GB0025173D0 (en) | Therapeutic agents | |
| GB0223040D0 (en) | Therapeutic compounds | |
| HK1089376A1 (en) | Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions | |
| GB0005251D0 (en) | Therapeutic compounds | |
| ZA200110504B (en) | Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria. | |
| IL158181A0 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| WO2001035950A3 (en) | Benzamide therapeutics and methods for treating inflammatory bowel disease | |
| WO2004105737A3 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
| MXPA03003741A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
| YU57803A (sh) | Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja | |
| AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
| EP1116488A3 (en) | Treatment of inflammatory Bowel disease | |
| TR200502061T2 (tr) | IL-18 inhibitörlerinin kullanımı. | |
| MX2009004196A (es) | Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de enfermedades autoinmunes. | |
| AU2001295839A1 (en) | Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa | |
| HUP0300083A3 (en) | Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents | |
| SI1656372T1 (sl) | Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni | |
| EP1194162A4 (en) | COMPOSITIONS AND METHODS OF PREVENTING, TREATING AND DETECTING TUBERHULOSIS AND OTHER DISEASES |